Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC is developing products to treat several diseases and their debilitating comorbidities which cause reduced quality of life, increased medical costs and significant mortality. Comorbidities are a common consequence of sickle cell disease, chemotherapy, atherosclerosis, diabetes and many other diseases. - The company's lead product, SANGUINATE™, is focused on treating the comorbidities of sickle cell disease and hemorrhagic stroke - Prolong has a long-acting 3rd generation biologic in clinical development for the treatment of anemia, a comorbidity common with chronic kidney disease and cancer chemotherapy - Other products are also in development for comorbidities that result from diseases such as cardiovascular disorders and cancer ___________